News
-
The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 16 to 1 that the benefit of Avillion and AstraZeneca’s PT027 albuterol / budesonide MDI for the treatment of asthma in adults outweighs the risks. However, the… Read more . . .
-
CyanVac subsidiary Blue Lake Biotechnology has presented interim data from a Phase 1 trial of its BLB201 intranasal vaccine against respiratory syncytial virus (RSV) that demonstrate an increase in serum antibody responses from baseline in… Read more . . .
-
Tyrvaya varenicline nasal spray maker Oyster Point Pharma announced that its board of directors has approved the company’s plans to be acquired by Viatris for $11 per share at closing plus up to $2 per… Read more . . .
-
Meissa Vaccines is presenting Phase 1c data from a study of its MV-012-968 intranasal live attenuated RSV vaccine candidate in 66 children aged 6-36 months demonstrating that the highest dose of the vaccine evaluated induced… Read more . . .
-
According to modeling software company Simulations Plus, the FDA has awarded the company a contract for a project that is intended to improve models of pulmonary absorption of inhaled drugs, with a goal of creating “the… Read more . . .
-
TFF Pharmaceuticals announced that it has been working with Aptar Pharma on a project to develop dry powder vaccines based on TFF’s thin film freezing particle manufacturing platform and Aptar Pharma’s Unidose (UDS) nasal powder… Read more . . .
-
Apeiron Respiratory Therapies (Arest), a subsidiary of Invios, announced that a Phase 1 SAD/MAD study of its APN01 nebulized alunacedase alfa in 40 healthy subjects met all endpoints. Both Arest and Invios were spun off… Read more . . .
-
OINDP testing experts Copley Scientific have announced the introduction of the new Volume and Resistance Compensator (VRC), which is designed to make abbreviated impactor measurements (AIM) more comparable to full resolution impactor measurements when measuring… Read more . . .
-
Renovion and the COPD Foundation have announced the initiation of a Phase 2 trial of Renovion’s ARINA-1 nebulized glutathione / bicarbonate / ascorbic acid in patients with non-CF bronchiectasis (NCFBE). The COPD Foundation announced in… Read more . . .
-
Pieris Pharmaceuticals has announced the initiation of a Phase 1 study of PRS-220, an anticalin inhalation solution that targets connective tissue growth factor (CTGF), which the company is developing for the treatment of fibrotic lung… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan